Veeva Systems Inc. Stock

Equities

VEEV

US9224751084

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:02 2024-05-31 pm EDT 5-day change 1st Jan Change
174.2 USD -10.27% Intraday chart for Veeva Systems Inc. -14.83% -9.49%
Sales 2025 * 2.71B Sales 2026 * 3.07B Capitalization 31.38B
Net income 2025 * 674M Net income 2026 * 770M EV / Sales 2025 * 9.7 x
Net cash position 2025 * 5.07B Net cash position 2026 * 6.33B EV / Sales 2026 * 8.16 x
P/E ratio 2025 *
48 x
P/E ratio 2026 *
42.5 x
Employees 7,172
Yield 2025 *
-
Yield 2026 *
-
Free-Float 91.04%
More Fundamentals * Assessed data
Dynamic Chart
Stifel Nicolaus Adjusts Veeva Systems Price Target to $210 From $250, Maintains Buy Rating MT
Evercore ISI Cuts Price Target on Veeva Systems to $200 From $230, Maintains In-Line Rating MT
UBS Adjusts Veeva Systems Price Target to $185 From $235, Maintains Neutral Rating MT
Baird Adjusts Veeva Systems' Price Target to $245 From $255, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday MT
Piper Sandler Cuts Price Target on Veeva Systems to $235 From $245, Maintains Overweight Rating MT
Morgan Stanley Cuts Price Target on Veeva Systems to $173 From $210, Says Billings 'Continue to Disappoint,' Keeps Underweight Rating MT
Veeva Systems Fiscal Q1 Non-GAAP Earnings, Sales Rise But Full-Year Revenue Guidance Cut; Shares Fall Premarket MT
Veeva Systems Fiscal Q1 Non-GAAP EPS, Revenue Rise; FY 2025 Revenue Guidance Cut; Shares Fall After Hour MT
Transcript : Veeva Systems Inc., Q1 2025 Earnings Call, May 30, 2024
Earnings Flash (VEEV) VEEVA SYSTEMS Reports Q1 EPS $1.50, vs. Street Est of $1.43 MT
Earnings Flash (VEEV) VEEVA SYSTEMS Posts Q1 Revenue $650.3M, vs. Street Est of $642M MT
Veeva Systems Inc. Provides Earnings Guidance for the Second Quarter Ending July 31, 2024 and for the Fiscal Year Ending January 31, 2025 CI
Veeva Systems Guides For FY 2025 EPS of $6.16 on Revenue of $2.70-$2.71 Billion, vs CIQ Analyst Consensus of $6.15/Share on Revenue of $2.73 Billion MT
Veeva Systems Guides For Q2 EPS of $1.53-$1.54 on Revenue of $666-$669 Million, vs CIQ Analyst Consensus of $1.52/Share on Revenue of $675 Million MT
More news
1 day-10.27%
1 week-14.83%
Current month-12.24%
1 month-12.24%
3 months-21.51%
6 months-0.03%
Current year-9.49%
More quotes
1 week
170.25
Extreme 170.25
204.54
1 month
170.25
Extreme 170.25
213.00
Current year
170.25
Extreme 170.25
236.90
1 year
162.72
Extreme 162.72
236.90
3 years
151.02
Extreme 151.02
343.96
5 years
118.11
Extreme 118.11
343.96
10 years
19.51
Extreme 19.51
343.96
More quotes
Managers TitleAgeSince
Founder 59 07-01-11
Founder 51 07-01-11
Director of Finance/CFO 56 10-01-31
Members of the board TitleAgeSince
Director/Board Member 67 22-01-20
Director/Board Member 66 14-07-06
Director/Board Member 62 17-06-20
More insiders
Date Price Change Volume
24-05-31 174.2 -10.27% 4,629,509
24-05-30 194.2 -3.15% 1,985,770
24-05-29 200.5 -1.28% 1,114,938
24-05-28 203.1 -0.39% 819,062
24-05-24 203.9 -0.34% 600,576

Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT

More quotes
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. The Company offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and their strategic business functions from research and development (R&D) through commercialization. The Company’s three product categories: Veeva Development Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Vault Clinical advances clinical trial execution by providing a complete and connected technology ecosystem. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Its software offerings include Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix. Its data offerings include Veeva OpenData, Veeva Link, and Veeva Compass.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
174.2 USD
Average target price
229.5 USD
Spread / Average Target
+31.73%
Consensus